Corbus Pharmaceuticals Holdings Management
Management criteria checks 3/4
Corbus Pharmaceuticals Holdings' CEO is Yuval Cohen, appointed in Apr 2014, has a tenure of 10.58 years. total yearly compensation is $1.14M, comprised of 52.6% salary and 47.4% bonuses, including company stock and options. directly owns 0.027% of the company’s shares, worth €58.40K. The average tenure of the management team and the board of directors is 6.9 years and 5.1 years respectively.
Key information
Yuval Cohen
Chief executive officer
US$1.1m
Total compensation
| CEO salary percentage | 52.6% |
| CEO tenure | 10.6yrs |
| CEO ownership | 0.03% |
| Management average tenure | 6.9yrs |
| Board average tenure | 5.1yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$35m |
| Mar 31 2024 | n/a | n/a | -US$34m |
| Dec 31 2023 | US$1m | US$599k | -US$45m |
| Sep 30 2023 | n/a | n/a | -US$47m |
| Jun 30 2023 | n/a | n/a | -US$46m |
| Mar 31 2023 | n/a | n/a | -US$51m |
| Dec 31 2022 | US$1m | US$598k | -US$42m |
| Sep 30 2022 | n/a | n/a | -US$42m |
| Jun 30 2022 | n/a | n/a | -US$35m |
| Mar 31 2022 | n/a | n/a | -US$39m |
| Dec 31 2021 | US$5m | US$579k | -US$46m |
| Sep 30 2021 | n/a | n/a | -US$44m |
| Jun 30 2021 | n/a | n/a | -US$77m |
| Mar 31 2021 | n/a | n/a | -US$98m |
| Dec 31 2020 | US$3m | US$559k | -US$111m |
| Sep 30 2020 | n/a | n/a | -US$129m |
| Jun 30 2020 | n/a | n/a | -US$115m |
| Mar 31 2020 | n/a | n/a | -US$75m |
| Dec 31 2019 | US$4m | US$559k | -US$71m |
| Sep 30 2019 | n/a | n/a | -US$62m |
| Jun 30 2019 | n/a | n/a | -US$56m |
| Mar 31 2019 | n/a | n/a | -US$70m |
| Dec 31 2018 | US$4m | US$540k | -US$56m |
| Sep 30 2018 | n/a | n/a | -US$49m |
| Jun 30 2018 | n/a | n/a | -US$41m |
| Mar 31 2018 | n/a | n/a | -US$37m |
| Dec 31 2017 | US$3m | US$463k | -US$32m |
Compensation vs Market: Yuval's total compensation ($USD1.14M) is above average for companies of similar size in the German market ($USD819.40K).
Compensation vs Earnings: Yuval's compensation has been consistent with company performance over the past year.
CEO
Yuval Cohen (49 yo)
10.6yrs
Tenure
US$1,137,622
Compensation
Dr. Yuval Cohen, Ph.D. has been the Chief Executive Officer and Director at Corbus Pharmaceuticals Holdings, Inc. since April 11, 2014. Dr. Cohen served as Senior Vice President at Celsus Therapeutics Plc...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 10.6yrs | US$1.14m | 0.027% € 58.4k | |
| Chief Financial Officer | 10.6yrs | US$717.26k | 0.070% € 150.4k | |
| Head of Corporate Communications & Patient Advocacy | no data | no data | no data | |
| Vice President of Human Resources | 3.3yrs | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
6.9yrs
Average Tenure
50yo
Average Age
Experienced Management: 3371's management team is seasoned and experienced (6.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 10.6yrs | US$1.14m | 0.027% € 58.4k | |
| Independent Chairman | 10.8yrs | US$120.66k | 0.025% € 54.3k | |
| Director | less than a year | no data | no data | |
| Independent Director | 2.2yrs | US$90.51k | 0% € 0 | |
| Independent Director | 6.4yrs | US$109.74k | 0.00027% € 580.1 | |
| Independent Director | 1.7yrs | US$94.21k | 0% € 0 | |
| Independent Director | 5.6yrs | US$104.42k | 0% € 0 | |
| Independent Director | 4.7yrs | US$89.41k | 0% € 0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
5.1yrs
Average Tenure
54.5yo
Average Age
Experienced Board: 3371's board of directors are considered experienced (5.1 years average tenure).